KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Cash from Operations (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Cash from Operations readings, the most recent being 291960000.0 for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 5700.61% to 291960000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 347369000.0, a 767.76% increase, with the full-year FY2025 number at 347369000.0, up 767.76% from a year prior.
  • Cash from Operations hit 291960000.0 in Q4 2025 for Biocryst Pharmaceuticals, up from 41624000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 291960000.0 in Q4 2025 to a low of 77800000.0 in Q1 2022.
  • Median Cash from Operations over the past 5 years was 23562500.0 (2021), compared with a mean of 5189950.0.
  • Biggest five-year swings in Cash from Operations: plummeted 162.06% in 2021 and later surged 5700.61% in 2025.
  • Biocryst Pharmaceuticals' Cash from Operations stood at 32459000.0 in 2021, then rose by 26.53% to 23849000.0 in 2022, then surged by 62.61% to 8918000.0 in 2023, then soared by 41.55% to 5213000.0 in 2024, then surged by 5700.61% to 291960000.0 in 2025.
  • The last three reported values for Cash from Operations were 291960000.0 (Q4 2025), 41624000.0 (Q3 2025), and 41302000.0 (Q2 2025) per Business Quant data.